Dr. Reddy’s Laboratories announced the launch of Sildenafil (20 mg), a bioequivalent generic version of Revatio tablets in the United States’ markets on November 16.

The launch follows approval granted by the U.S. Food and Drug Administration to Dr. Reddy’s abbreviated new drug application for Sildenafil tablets and they would be available in 90 count bottle sizes. The Revatio brand, a registered trademark of Pfizer Inc., had sales of $338.67 million in the U.S., according to a press release.